KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

NovoCure (NVCR) Operating Expenses (2016 - 2026)

NovoCure's Operating Expenses history spans 13 years, with the latest figure at $202.5 million for Q1 2026.

  • On a quarterly basis, Operating Expenses rose 31.24% to $202.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $690.5 million, a 6.8% increase, with the full-year FY2025 number at $642.3 million, up 0.59% from a year prior.
  • Operating Expenses hit $202.5 million in Q1 2026 for NovoCure, up from $172.6 million in the prior quarter.
  • Over the last five years, Operating Expenses for NVCR hit a ceiling of $202.5 million in Q1 2026 and a floor of $110.6 million in Q1 2022.
  • Historically, Operating Expenses has averaged $153.5 million across 5 years, with a median of $152.9 million in 2023.
  • Biggest five-year swings in Operating Expenses: surged 38.14% in 2023 and later dropped 9.69% in 2025.
  • Tracing NVCR's Operating Expenses over 5 years: stood at $142.5 million in 2022, then increased by 7.31% to $152.9 million in 2023, then increased by 24.95% to $191.1 million in 2024, then dropped by 9.69% to $172.6 million in 2025, then increased by 17.36% to $202.5 million in 2026.
  • Business Quant data shows Operating Expenses for NVCR at $202.5 million in Q1 2026, $172.6 million in Q4 2025, and $158.5 million in Q3 2025.